We’re pleased to announce our latest partnership with Willis Knighton Cancer Center. They’ve integrated MyoStrain into their radiotherapy program to enhance early detection of cardiotoxicity in cancer patients. With our rapid, 10-minute MRI-based cardiac assessment—requiring no contrast—clinicians can monitor subtle changes in heart function to tailor patient management. As Dr. Lane R. Rosen explains, “Early detection allows us to take early action, possibly reversing the process before the damage becomes permanent.” Learn more about this exciting collaboration in Willis Knighton’s full press release: https://bit.ly/4hVe7C5
Myocardial Solutions
医疗设备制造业
Morrisville，North Carolina 1,465 位关注者
Providing novel MRI-based clinical informatics to transform cardiac care and standardize cardiac population management
关于我们
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain?, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. This novel cardiac tool leverages the power of high-speed MR imaging to help physicians detect and measure the effects of cardiotoxicity during cancer treatments. Physicians are using MyoStrain as a critical solution to holistically evaluate and protect patient heart health without interfering with oncology care. Today, with mounting evidence that many oncology treatments cause cardiotoxicity, new cancer patients and survivors are at an increased risk of cardiovascular disease. Unfortunately, diagnostics often cannot detect cardiotoxicity until symptoms occur, which is usually a sign of cardiac damage. The MyoStrain test works by quantifying segmental strain across 48 segments of the heart. This safe and rapid test produces a comprehensive report and MyoHealth? Score, a single number that helps indicate patient heart health and enables physicians to manage cardio-protection over time. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
- 网站
-
https://myocardialsolutions.com
Myocardial Solutions的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 11-50 人
- 总部
- Morrisville，North Carolina
- 类型
- 私人持股
- 创立
- 2016
- 领域
- Cardio-Oncology、Oncology、Cancer Care、Heart Failure Management、Preventative Cardiology、Chest Pain Triage、Stress Testing、Early Detection、Proactive Diagnostics、Personalized Medicine、Value-based Care、COVID 19、Cardiac MRI、Cardio-Protection、Patient Management、Long-term Monitoring、Rapid Heart Function Testing和Non-invasive and Safe Test
地点
-
主要
获取路线
808 Aviation Pkwy
Suite 700
US，North Carolina，Morrisville，27560
Myocardial Solutions员工
动态
-
Responsable Comunicación y Marketing Vithas Málaga. ? También ayudo a que empresas y profesionales atraigan más clientes, apareciendo en los principales medios de comunicación sin pagar por publicidad.
He de reconocer que hay tecnologías médicas que me "enganchan" especialmente. Una de ellas es el software cardiológico MyoStrain de Myocardial Solutions Hoy en Vithas Málaga hemos firmado un nuevo convenio de colaboración con la sede provincial de la Asociación Espa?ola Contra el Cáncer. Dicho acuerdo facilita a sus asociados el acceso a esta tecnología la cual, entre otras ventajas, permite identificar y evaluar correctamente los posibles da?os cardiológicos que los diferentes tratamientos quimioterápicos hayan podido dejar en los pacientes que han superado un cáncer. Más info aquí ?? https://lnkd.in/dqpYYkdY #diamundialcontraelcancer #corazon #cancer
-
-
Vithas Málaga Hospital and AECC have joined forces to enhance cardiac care for cancer patients. On February 5, 2025, Jose María Baena (Vithas Málaga) and Carmen Litrán (AECC) signed an agreement to provide AECC members with access to MyoStrain cardiology software. This cutting-edge, noninvasive 10-minute cardiac MRI test enables early detection of cardiotoxicity during and after cancer treatment. Together, we’re advancing early cardiac care and improving patient outcomes. https://bit.ly/4hpkA8l
-
-
Myocardial Solutions Mobile 1.5T Philips MRI Scanner is making a stop at Nemours Children’s Hospital in Florida, and introducing them to MyoStrain - a 10 min, no contrast heart scan that helps physicians detect, manage and predict early heart dysfunction. By bringing advanced MyoStrain? technology directly to hospitals, we are enhancing access to rapid, non-invasive cardiac assessments—helping physicians detect and monitor heart health with precision.
-
-
Philips has partnered with Myocardial Solutions to advance AI-enabled cardiac magnetic resonance (CMR) imaging, focusing on early heart disease detection in cancer patients and survivors. This collaboration aims to address cardiotoxicity caused by cancer therapies, potentially improving survival rates and quality of life. The partnership introduces advanced imaging technologies like Fast-SENC and MyoStrain, which can detect subtle changes in heart function across 48 segments in just 10 minutes. Philips' SmartSpeed technology, integrated with AI-driven Compressed SENSE and Adaptive-CS-Net, boosts scan speed and accuracy, reducing exam times by up to 3x while maintaining high image quality. Ioannis Panagiotelis, Philips MR business leader, emphasized the partnership's potential: "By combining our innovative BlueSeal innovation and SmartSpeed technologies with Myocardial Solutions' specialized expertise in cardiac care, we aim to redefine the standard of cardiac care, environmental responsibility, and accessibility." Additionally, Philips' BlueSeal system with helium-free technology addresses environmental challenges by reducing helium dependency and lowering carbon footprint, while also bringing hospital-quality imaging to rural and underserved areas. https://lnkd.in/eXTKVQny ?? Follow Practical Patient Care to receive the latest news daily and to subscribe to our weekly newsletter. #PracticalPatientCare #AIinCardiology #CancerCare #MedicalImaging #HealthcareInnovation
-
-
?? Philips, Myocardial Solutions partner to boost cardiac imaging using AI The collaboration aims to improve survival rates and enhance the quality of life for people undergoing cancer treatment, bridging a gap between heart and cancer care. According to the Dutch medical technology company, early detection of heart disease may benefit cancer survivors taking treatment for cardiotoxicity, caused due to cancer therapies. Both companies leverage advanced imaging technologies, such as Fast-SENC and MyoStrain, to detect early signs of cardiotoxicity in patients undergoing cancer treatments. By measuring subtle changes in heart function, the technologies enable early detection of heart failure across 48 heart segments in 10 minutes. Read more online: https://lnkd.in/eCtxqCTB ?? Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing
-
-
Uncover the diagnostic prowess of MyoStrain in "Hyperventilation/Breath-Hold Maneuver for Myocardial Ischemia Detection by Strain-Encoded CMR" (https://lnkd.in/gBNR7rhz) A needle-free stress protocol that's safe, simple, and speedy, offering clinicians an avenue for improving coronary artery disease diagnosis. Learn more about MyoStrain here: https://lnkd.in/gMnPmKGm
-
-
Strategic Insights for Healthcare Leaders: The article, “More Awareness Needed of Heart Events Tied to Breast Cancer Drugs,” (https://bit.ly/48hfKoL) emphasizes the role of ejection fraction and global longitudinal strain. The PREFECT study showed that MyoStrain predicted and detected subclinical cardiotoxicity in patients with normal LVEF before changes in global longitudinal strain: https://bit.ly/3RpkRfJ Hospital CEOs and doctors have the opportunity to leverage MyoStrain's advanced capabilities, including segmental strain analysis, for a holistic approach to cardiac monitoring. Stay at the forefront of medical excellence. Learn more here: https://bit.ly/46VFerp
-
-
Senior Global Portfolio Manager @Philips // Design strategy to shape healthcare landscape with technological innovations
Did you know that while advances in cancer treatments have led to increased survival rates, many who beat cancer may still face a hidden danger? ???? Cardiotoxicity, or heart damage from chemotherapy, is becoming a leading cause of death for cancer survivors years after treatment! A groundbreaking study found that cardiovascular magnetic resonance (CMR) using fast-strain-encoded (Fast-SENC) imaging by Philips (https://lnkd.in/eipCqj2H) and MyoStrain by Myocardial Solutions - can detect early signs of cardiotoxicity, potentially saving lives. The innovative metric "normal myocardium (%)" has shown remarkable accuracy in identifying patients at risk, even before symptoms emerge. This means proactive treatment can begin sooner, leading to better outcomes! ?? It's time we focus not just on surviving cancer but also on safeguarding our hearts in the process. Let's raise awareness about this crucial aspect of cancer care! ?? Myocardial Solutions Rafael R. Sebastian Kelle (MD, FESC, FAHA, FSCMR) Tim Leiner, MD PhD EBCR Atul Gupta, MD #Cardiotoxicity #CardioOncology #CardiacCare #WhyCMR https://lnkd.in/eV5nzu2k
Discover key findings from the PREFECT study in the article “Multiparametric Early Detection and Prediction of Cardiotoxicity.” The study demonstrates how MyoStrain? detects early cardiotoxicity in cancer patients, helping cardio-oncologists take proactive measures to protect heart health. Learn more at the link in our bio. (https://lnkd.in/g72qBA5C)
-